Keywords: antisoma, asa404, fails, ovarian, cancer, trial, uk-based

Antisoma's ASA404 fails in ovarian cancer trial

Article | 23 July 2007

Print This

UK-based cancer drug developer Antisoma says that new data from a Phase II trial of its chemotherapy adjuvant ASA404 (formerly ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in